Page 1358 - Williams Hematology ( PDFDrive )

1332 Part X: Malignant Myeloid Diseases Chapter 86: Primary Myelofibrosis 1333

65. Garimella R, Kacena MA, Tague SE, et al: Expression of bone morphogenetic proteins 98. Apaja-Sarkkinen M, Autio-Harmainen H, Alavaikko M, et al: Immunohistochemical
and their receptors in the bone marrow megakaryocytes of GATA-1(low) mice: A pos- study of basement membrane proteins and type III procollagen in myelofibrosis. Br J
sible role in osteosclerosis. J Histochem Cytochem 55:745, 2007. Haematol 63:571, 1986.
66. Levine RL, Gilliland DG: Myeloproliferative disorders. Blood 112:2190, 2008. 99. Hasselbalch H, Junker P, Lisse I, et al: Serum markers for type IV collagen and type III
67. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic
in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelo- myeloproliferative disorders. Am J Hematol 23:101, 1986.
fibrosis. Cancer Cell 7:387, 2005. 100. Reilly JT: Pathogenesis of idiopathic myelofibrosis: Role of growth factors. J Clin Pathol
68. Kilpivaara O, Levine RL: JAK2 and MPL mutations in myeloproliferative neoplasms: 45:461, 1992.
Discovery and science. Leukemia 22:1813, 2008. 101. Charron D, Robert L, Couty MC, Binet JL: Biochemical and histological analysis of
69. Wernig G, Mercher T, Okabe R, et al: Expression of Jak2V617F causes a polycythemia bone marrow collagen in myelofibrosis. Br J Haematol 41:151, 1979.
vera-like disease with associated myelofibrosis in a murine bone marrow transplant 102. Podolak-Dawidziak M, Wróbel T, Jelen M: Serum concentration of the amino terminal
model. Blood 107:4274, 2006. peptide of type III procollagen (PIIINP) in patients with myeloproliferative disorders
70. Lacout C, Pisani DF, Tulliez M, et al: JAK2V617F expression in murine hematopoi- (MPD). Pol Arch Med Wewn 99:24, 1998.
etic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 103. Gay S, Gay RE, Prohal JT: Immunohistological studies of bone marrow collagen, in
108:1652, 2006. Myelofibrosis and the Biology of Connective Tissue, edited by Berk P, Castro-Malaspina
71. Zaleskas VM, Krause DS, Lazarides K, et al: Molecular pathogenesis and therapy of H, Wasserman LR, p 291. Alan R. Liss, New York, 1984.
polycythemia induced in mice by JAK2 V617F. PLoS One 1:e18, 2006. 104. Hasselbalch H, Junker P, Horslev-Patersen K, et al: Procollagen type III amino-terminal
72. Kralovics R, Guan Y, Prchal JT: Acquired uniparental disomy of chromosome 9p is a peptide in serum in idiopathic myelofibrosis and allied conditions. Am J Hematol 33:18,
frequent stem cell defect in polycythemia vera. Exp Hematol 30:229, 2002. 1990.
73. Tiedt R, Hao-Shen H, Sobas MA, et al: Ratio of mutant JAK2-V617F to wild-type Jak2 105. Reilly JT, Nash JRG, Mackie MJ, McVerry BA: Endothelial cell proliferation in myelofi-
determines the MPD phenotypes in transgenic mice. Blood 111:3931, 2008. brosis. Br J Haematol 60:625, 1985.
74. Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC: The JAK2 V617F allele burden 106. Baglin TP, Crocker MA, Timmins A, et al: Bone marrow hypervascularity in patients
in essential thrombocythemia, polycythemia vera and primary myelofibrosis—Impact with myelofibrosis identified by infrared thermography. Clin Lab Haematol 13:341,
on disease phenotype. Eur J Haematol 79:508, 2007. 1991.
75. Pikman Y, Lee BH, Mercher T, et al: MPLW515L is a novel somatic activating mutation 107. Bock O, Neuse J, Hussein K, et al: Aberrant collagenase expression in chronic idiopathic
in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270, 2006. myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am
76. Pardanani AD, Levine RL, Lasho T, et al: MPL515 mutations in myeloproliferative and J Pathol 169:471, 2006.
other myeloid disorders: A study of 1182 patients. Blood 108:3472, 2006. 108. Bock O, Höftmann J, Theophile K, et al: Bone morphogenetic proteins are overex-
77. Tefferi A: JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 49:388, pressed in the bone marrow of primary myelofibrosis and are apparently induced by
2008. fibrogenic cytokines. Am J Pathol 172:951, 2008.
78. Tefferi A: Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and 109. Dolan G, Forrest P, Eastham J, et al: Serum laminin, procollagen terminal peptide III
management. Am J Hematol 88:141, 2013. and thrombocyte platelet derived growth factor concentrations in idiopathic myelofi-
79. Klampfl T, Gisslinger H, Harutyunyan AS, et al: Somatic mutations of calreticulin in brosis. Br J Haematol 77(Suppl 1):73, 1991.
myeloproliferative neoplasms. N Engl J Med 369:2379, 2013. 110. Reilly JT, Nash JRG, Mackie MJ, McVerry BA: Immunoenzymatic detection of fibronec-
80. Nangalia J, Massie CE, Baxter EJ, et al: Somatic CALR mutations in myeloproliferative tin in normal and pathological haemopoietic tissue. Br J Haematol 59:497, 1985.
neoplasms with nonmutated JAK2. N Engl J Med 369:2391, 2013. 111. Hasselbalch H, Clemmensen I: Plasma fibronectin in idiopathic myelofibrosis and
81. Wang L, Swierczek SI, Drummond J, et al: Whole-exome sequencing of polycythemia related chronic myeloproliferative disorders. Scand J Clin Lab Invest 47:429, 1987.
vera revealed novel driver genes and somatic mutation shared by T-cells and granulo- 112. Soini Y, Kamel D, Apaja-Sarkkinen M, et al: Tenascin immunoreactivity in normal and
cytes. Leukemia 28:935, 2014. pathological bone marrow. J Clin Pathol 46:218, 1993.
82. Abu-Duhier FM, Goodeve AC, Care RS, et al: Mutational analysis of class III recep- 113. Reilly JT, Nash JRG: Vitronectin (serum spreading factor): Its localization in normal
tor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis. Br J Haematol and fibrotic tissue. J Clin Pathol 41:1269, 1988.
120:464, 2003. 114. Le Bousse-Kerdilès MC, Martyré MC, et al: Involvement of the fibrogenic cytokines,
83. Kawamata N, Ogawa S, Yamamoto G, et al: Genetic profiling of myeloproliferative dis- TGF-β and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol Biol 49:153,
orders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol 2001.
36(11):1477, 2008. 115. Rameshwar P, Oh HS, Yook C, Chang VT: Substance P-fibronectin cytokine interac-
84. Andrieux J, Demory JL, Dupriez B, et al: Dysregulation and overexpression of tions in myeloproliferative disorders with bone marrow fibrosis. Acta Haematol 109:1,
HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer 39:82, 2003.
2004. 116. Wang JC, Wong C, Kao WW: Immunoreactive prolylhydroxylase in patients with pri-
85. Bogani C, Ponziani V, Guglielmelli P, et al: Myeloproliferative Disorders Research Con- mary and secondary myelofibrosis. Br J Haematol 65:171, 1987.
sortium. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with 117. Barosi G, Costa A, Liberato LN, et al: Serum procollagen III peptide level correlates
primary myelofibrosis. Stem Cells 26:1920, 2008. with disease activity in myelofibrosis with myeloid metaplasia. Br J Haematol 72:16,
86. Rosti V, Massa M, Vannucchi AM, et al: The expression of CXCR4 is down-regulated on 1989.
the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol 118. Hochweiss S, Fruchtman S, Hahn EG, et al: Increased serum procollagen III amino-
Dis 38:280, 2007. terminal peptide in myelofibrosis. Am J Hematol 15:343, 1983.
87. Ciurea SO, Merchant D, Mahmud N, et al: Pivotal contributions of megakaryocytes to 119. Hasselbalch H, Junker P, Lisse I, et al: Circulating hyaluronan in the myelofibrosis/oste-
the biology of idiopathic myelofibrosis. Blood 110:986, 2007. omyelosclerosis syndrome and other myeloproliferative disorders. Am J Hematol 36:1,
88. Guglielmelli P, Zini R, Bogani C, et al: Molecular profiling of CD34+ cells in idiopathic 1991.
myelofibrosis identifies a set of disease-associated genes and reveals the clinical signifi- 120. Thiele J, Kvasnicka HM, Fischer R, Diehl V: Clinicopathological impact of the inter-
cance of Wilms’ tumor gene 1 (WT1). Stem Cells 25:165, 2007. activity between megakaryocytes and myeloid stroma in chronic myeloproliferative
89. Massa M, Rosti V, Ramajoli I, et al: Circulating CD34+, CD133+, and vascular endothe- disorders: A concise update. Leuk Lymphoma 24:463, 1997.
lial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with 121. Schmitt A, Drouin A, Masse J-M, et al: Polymorphonuclear neutrophil and megakary-
myeloid metaplasia. J Clin Oncol 23:5688, 2005. ocyte mutual involvement in myelofibrosis pathogenesis. Leuk Lymphoma 43:719,
90. Rosti V, Villani L, Riboni R, et al: Spleen endothelial cells from patients with myelofi- 2002.
brosis harbor the JAK2V617F mutation. Blood 121:360, 2013. 122. Frey BM, Rafii S, Teterson M, et al: Adenovector-mediated expression of human throm-
91. Giraudier S, Chagraoui H, Komura E, et al: Overexpression of FKBP51 in idiopathic bopoietin cDNA in immune-compromised mice: Insights into the pathophysiology of
myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. osteomyelofibrosis. J Immunol 160:691, 1998.
Blood 100:2932, 2002. 123. Rameshwar P, Chang VT, Thacker UF, Gascón P: Systemic transforming growth
92. Wang JC, Chen C, Lou LH, et al: Blood thrombopoietin, IL-6, and IL-11 levels in factor-beta in patients with bone marrow fibrosis-pathophysiological implications. Am
patients with agnogenic myeloid metaplasia. Leukemia 11:1827, 1997. J Hematol 59:133, 1998.
93. Moliterno AR, Hankins WD, Spivak JL: Impaired expression of the thrombopoietin 124. Rosenfeld M, Keating A, Bowen-Pope BF, et al: Responsiveness of the in vitro hemato-
receptor by patients with polycythemia vera. N Engl J Med 338:572, 1998. poietic microenvironment to platelet-derived growth factor. Leuk Res 9:427, 1985.
94. Prockop DJ, Kivirikko KI, Tuderman L, et al: The biosynthesis of collagen and its disor- 125. Bernabei PA, Arcangeli A, Casini M, et al: Platelet-derived growth factor(s) mitogenic
ders. N Engl J Med 301:13, 1979. activity in patients with myeloproliferative disease. Br J Haematol 63:353, 1986.
95. Bauermeister DE: Quantitation of bone marrow reticulin: A normal range. Am J Clin 126. Thiele J, Rompick V, Wagner S, Fischer R: Vascular architecture and collagen type IV in
Pathol 56:24, 1971. primary myelofibrosis and polycythemia vera. Br J Haematol 80:227, 1992.
96. Ivànyi JL, Mahunka M, Papp A, Telek B: Prognostic significance of bone marrow retic- 127. Johnston JB, Dalal BI, Israels SJ, et al: Deposition of transforming growth factor-β in the
ulum fibers in idiopathic myelofibrosis: Evolution of clinicopathological parameters in marrow in myelofibrosis, and the intracellular localization and secretion of TGF-β by
a scoring system. Haematologica 26:75, 1994. leukemic cells. Am J Clin Pathol 103:574, 1995.
97. McCarthy DM: Annotation: Fibrosis of the bone marrow: Content and causes. Br J 128. Martré M-C: TGF-β and megakaryocytes in the pathogenesis of myelofibrosis in mye-
Haematol 59:1, 1985. loproliferative disorders. Leuk Lymphoma 20:39, 1995.

Kaushansky_chapter 86_p1319-1340.indd 1333 9/18/15 10:24 AM